Royalty Pharma Q3 portfolio receipts up 15% to $735M; raises FY guidance to $2.75-2.8B

Royalty Pharma plc

2024-Q3 EPS reported $1.44 revenue$1,669,935,000

Royalty Receipts grew 15% to $732M; Portfolio Receipts $735M, driven by Trelegy, Evrysdi, cystic fibrosis franchise.
Full-year 2024 Portfolio Receipts guidance raised to $2.75B-$2.8B (from $2.7B-$2.775B); Royalty Receipts growth 11-13%.
Capital Deployment of ~$1.2B in Q3; acquired synthetic royalties on Niktimvo ($350M) and Yorvipath ($150M).
Net cash from operations $704M; repurchased ~3M shares for $95M during Q3; cash and equivalents $950M.
FDA approvals for Cobenfy (schizophrenia), Tremfya (ulcerative colitis), Voranigo (glioma) benefit royalty portfolio.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.